Tumours are composed of genotypically and phenotypically distinct cancer cell populations (clones), which are subject to a process of Darwinian evolution in response to changes in their local microenvironment, such as drug treatment. In a cancer patient, this process of continuous adaptation can be studied through next-generation sequencing of multiple tumour samples combined with appropriate bioinformatics and statistical methodologies. One family of statistical methods for clonal deconvolution seeks to identify groups of mutations and estimate the prevalence of each group in the tumour, while taking into account its purity and copy number profile. These methods have been used in the analysis of cross-sectional data, as well as for longitudinal data by discarding information on the timing of sample collection. Two key questions are how (in the case of longitudinal data) can we incorporate such information in our analyses and if there is any benefit in doing so. Regarding the first question, we incorporated information on the temporal spacing of longitudinally collected samples into standard non-parametric approaches for clonal deconvolution by modelling the time dependence of the prevalence of each clone as a Gaussian process. This permitted reconstruction of the temporal profile of the abundance of each clone continuously from several sparsely collected samples and without any strong prior assumptions on the functional form of this profile. Regarding the second question, we tested various model configurations on a range of whole genome, whole exome and targeted sequencing data from patients with chronic lymphocytic leukaemia, on liquid biopsy data from a patient with melanoma and on synthetic data. We demonstrate that incorporating temporal information in our analysis improves model performance, as long as data of sufficient volume and complexity are available for estimating free model parameters. We expect that our approach will be useful in cases where collecting a relatively long sequence of tumour samples is feasible, as in the case of liquid cancers (e.g. leukaemia) and liquid biopsies. The statistical methodology presented in this paper is freely available at github.com/dvav/clonosGP.
INTRODUCTION
It is well known that cancer cells undergo a process of Darwinian evolution in response to selective pressures in their local micro-environment, for example as a result of therapeutic intervention [1, 2] . This induces cell propagation and diversification during tumour growth, which result in a heterogeneous population of phylogenetically related, but genotypically and phenotypically distinct cancer cell populations, known as clones. Tumour heterogeneity is clinically important because it complicates the molecular profiling of tumours and enables the fittest cancer cells to escape treatment leading to relapse. Monitoring this process of continuous adaptation requires a detailed characterisation (through the use of next-generation sequencing, bioinformatics and statistical analysis) of the somatic aberrations harboured by the tumour at various time points over the course of the disease.
A major challenge in solving the problem of clonal deconvolution using bulk sequencing data is the fact that tumour heterogeneity is not directly observed, but rather inferred through the analysis of samples, each of which is a mixture of normal and cancer cells from various clones. Despite (or because of) this, clonal deconvolution has been the subject of much statistical innovation (see [3] [4] [5] [6] for a review). Current statistical methodologies seek to identify the number of clones in a tumour, their somatic mutation content, prevalence and phylogenetic relations and they can be used for the analysis of cross-sectional data (obtained, for example, through multiple biopsies from the same patient) or longitudinal data after discarding any information on the timing of tissue sample collection [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
In this paper, we pose the following two questions: a) how can we incorporate temporal spacing information in the analysis of sequentially collected samples (typically over several months or years) and b) is there any benefit in doing so? We begin with a standard Bayesian non-parametric model for clustering somatic mutations with similar observed frequencies, while simultaneously correcting for sample purity and local copy number variation. We extend this model by treating the cluster prevalences as functions of time, which follow a Gaussian process prior. The advantage of this approach is that we do not need to impose a particular functional form on the time dependence of cluster abundances, but only some general properties (e.g. smoothness, amplitude and time scale), which are estimated from the data. In return, we obtain a continuous reconstruction of the time course of each cluster during the course of the disease from a small number of sequentially collected samples. We test various model configurations on whole genome (WGS), whole exome (WES) and targeted sequencing (TGS) data from patients with chronic lymphocytic leukaemia (CLL; [23, 24] ), on data from the liquid biopsy of a patient with melanoma [25] and on synthetic data, and we demonstrate that incorporating temporal information in our analysis can boost the performance of clonal deconvolution.
METHODS
We present a series of models of increasing complexity starting with the statistical model for a single tumour sample.
Model for a single tumour sample
We assume that a tumour has been sequenced at N bi-allelic genomic loci harbouring somatic mutations. For each locus i, we can calculate the observed variant allele fraction (VAF) as the ratio r i /(r i + r ref i ), where r i and r ref i are the number of reads harbouring the alternative and reference alleles, respectively. The expected value θ i of the VAF for mutation i is a function f of the cancer cell fraction (CCF), i.e. the fractionφ i of cancer cells that harbour the mutation, θ i = f (φ i ). The population of cancer cells is partitioned in a finite, but unknown, number of clones, each harbouring a unique set of mutations. This implies that different mutations share the same CCF value, i.e. the mutation-specific fractions
are not all distinct. We model this structure with a Dirichlet Process prior onφ i with concentration parameter α and a uniform base distribution G 0 ≡ U(0, 1) [26, 27] . Using the stick-breaking representation of the Dirichlet Process,φ i is modelled as an infinite mixture,
where δ φ k (·) is the Dirac delta function centred at φ k and B(·, ·) indicates a beta distribution.
The uniform prior on the mean of the beta function (1 + a) −1 implies that the prior on the concentration parameter is α ∼ (1 + α) −2 , which is similar to the standard exponential distribution, but with thicker tail. In practice, we truncate the above infinite sum at a value K larger than the maximum possible number of clones expected in the data (here taken equal to 20).
Joint model for clonally-related tumor samples
The above model can be extended to multiple clonally-related samples by allowing the CCF variables to vary between samples [9, 28] . For M samples (and truncation K), we have:
where the rest of the model remains the same as for the one-sample case. Effectively, we incorporate multiple samples in the model by allowing the cluster centres φ jk to vary across samples. As a prelude to the next section, we note that the transformed variable ψ jk = log φ jk − log(1 − φ jk ) follows a standard logistic distribution, ψ jk ∼ Logistic(0, 1). Below, instead of the logistic distribution, we use a parametrised multivariate normal distribution, as explained in more detail in the next section.
Single-output Gaussian Process model for longitudinal tumour samples
The above model does not take into account the temporal spacing of the M samples, in case these have been collected longitudinally. If such information is indeed available, it can be included in the model by treating the transformed CCF variables as functions of time, ψ k (t).
On these functions, we impose a Gaussian Process prior [26, 29, 30] :
where the kernel function κ(t, t ) encodes the covariance of ψ k (t) at times t and t . This non-parametric approach permits modelling the time-dependency of the transformed CCF variables without any strong prior assumptions on the functional form of this dependency.
The above implies that if M samples have been collected at times t 1 = 0, . . . , t j , . . . , t M = 1, then the variables ψ jk = ψ k (t j ) follow a multivariate Normal distribution:
where 0 M is the M -dimensional zero vector. The elements of the covariance matrix K M = {κ(t j , t j )} j,j encode the covariance between the values of ψ k (t) at all possible pairs of sampling times t j and t j .
We consider kernels of the form κ(t, t ) = h 2 g τ (t, t ), where h is an amplitude parameter, while the function g τ (t, t ), which is parametrised by an inverse squared time scale parameter τ , takes any of the following forms: a) exponential:
)e − √ 5τ |t−t | and d) exponentiated quadratic: g τ (t, t ) = e −τ (t−t ) 2 /2 . These four kernels are members of the Matern family of covariance functions ordered in terms of increasing smoothness [29] . Finally, we impose gamma priors on the amplitude and time scale parameters, h 2 ∼ G(1, 1) and τ ∼ G(1, 1).
Multi-output Gaussian Process model for longitudinal tumour samples
In the above model, the cluster-specific scalar-valued functions ψ k (t) share the same Gaussian Process prior, but they are otherwise independent. We can directly model possible correlations between different clusters (i.e. different values of k) by assuming that the vector-valued function of time, ψ(t) = {ψ k (t)} K k=1 , follows a Gaussian Process prior:
where λ K (t, t ) is a matrix-valued kernel encoding the K × K covariance matrix between vectors ψ(t) and ψ(t ). Given M longitudinally observed samples, the above implies that the matrix of CCF values Ψ M ×K = {ψ jk } j,k follows a multivariate Normal distribution of dimensionality M K:
where the operator vec(·) vectorises its matrix argument by stacking its columns on top of each other, 0 M ×K is a matrix of zeros and Λ M K×M K is a positive semi-definite block matrix encoding the covariance between ψ jk and ψ j k .
Assuming that the above kernel is separable [31] , we can write the factorisation λ K (t, t ) = g τ (t, t )Σ K , where g τ (t, t ) is the same as in the previous section. Σ K is a positive semidefinite matrix factorised as Σ K = DCD, where D = diag(h 1 , . . . , h K ) and C ∝ |C| η−1 is a correlation matrix following the LKJ prior [32] with concentration parameter η. A value of η = 1 implies a uniform prior over correlation matrices, while η = 2 (the value we adopt here) concentrates more probability mass around the identity matrix. This structure for Σ K implies both cluster-specific amplitudes h 2 k , as well as correlations between clusters. Alternatively, we can assume that Σ K = diag(h 2 1 , . . . , h 2 K ), which implies that different clusters have different values of the amplitude parameters h 2 k , but are otherwise uncorrelated.
Finally, we examine the case where Λ M K×M K is a block-diagonal matrix, with each of the K matrices along its main diagonal induced by the kernel κ(t, t ) = h 2 k g τ k (t, t ), where both amplitude h 2 k and time scale τ k parameters are cluster-specific, but the clusters are otherwise uncorrelated.
Relation between VAF and CCF
In this section, we give more details about the form of the function θ ij = f (φ ij ), which encodes the relationship between VAF and CCF of mutation i in sample j. Each sample is viewed as a mixture of three cell populations [9] : a) a normal population of C N j non-cancer cells, b) a reference population of C R ij cancer cells, which do not harbour mutation i and c) a variant population of C V ij cancer cells, which harbour mutation i. The total number of cancer cells in the sample is
The reference and variant populations may each be further subdivided into sub-populations, where a different number of chromosomes covers locus i in each sub-population. The total number of chromosomes in the normal, reference and variant populations overlapping locus i in sample j are, respectively, equal to 
is the average number of chromosomes per cell harbouring mutation i in sample j in the variant cancer cell population (also known as multiplicity).
We write:
. At this stage, two simplifying assumptions are often made: a) there are no subclonal copy number events, which implies that d V ij , D V ij and D R ij are integers, and b) the reference and variant cancer cell populations have the same copy number profile at locus i in sample j, i.e.
Under these assumptions, the above expression simplifies to:
. The quantities ρ j and D ij can be independently estimated (e.g. using software such as ASCAT [33] , ABSOLUTE [34] , TITAN [35] and others) and they are considered fixed. One way to approximate the multiplicity
. Then, we estimate d V ij using the following rule:
For a justification of this estimation procedure, see [4] .
Observation models
We complete the above models by introducing expressions for the distribution of the read counts r ij harbouring mutation i in sample j. Since high-throughput sequencing data often exhibit over-dispersion, we consider a beta-binomial model:
where R ij is the sum of reads harbouring the alternative and reference alleles at locus i in sample j and 1/v j is a sample-specific dispersion parameter. In the absence of over-dispersion (i.e. when v j → ∞ ), the above reduces to the binomial model,
Inference
The above models were implemented using the Python-based probabilistic programming language PyMC3 v3.8 [36] and inference was conducted using Automatic Differentiation Vari-ational Inference (ADVI; [37] ), instead of developing bespoke estimation algorithms, which is a rather laborious process particularly when multiple candidate models are considered [38] [39] [40] . Variational inference (VI; [41, 42] ) is a computationally efficient approach for Bayesian inference, which aims to approximate the posterior density p(z|y) of latent variables z given data y using a surrogate probability density q θ (z) parametrised by a vector of variational parameters θ. In our case, the data y are the locus-and sample-specific read counts r ij and R ij , the local copy numbers D ij , the sample-specific purities ρ j and the sample collection times t j , while the latent variables z are the cancer cell fractions φ jk , the cluster weights w k , the amplitudes h 2 k , the time-scales τ k and the sample-specific dispersions v j . VI approximates p(z|y) by maximising the lower bound of the marginal likelihood (or evidence) p(y), which is known as the evidence lower bound (ELBO), with respect to the variational parameters θ:
Maximising the ELBO is equivalent to jointly maximising the entropy term (which leads to a more spread out variational distribution q and prevents overfitting) and minimising the average energy term (i.e. the discrepancy between q and p). Furthermore, the maximised ELBO, being a lower bound of the evidence p(y), can be used for model comparison (see below).
Performance metrics
We fit the above models against actual or simulated tumour samples (see Results). In the case of actual data, the ground truth (i.e. the actual clonal structure of each tumour sample) is unknown. In this case, we compare the performance of different models using the maximised ELBO (with a higher value indicating a better model). In the case of simulated data, the ground truth is known a priori and different models are compared using the Adjusted Rand Index (ARI), as implemented in the Python package scikit-learn v0.22 [43] . ARI takes values between -1 and 1, with a value close to 1 or -1 indicating close agreement or disagreement to the ground truth, respectively, while a value close to 0 indicates random assignment of mutations to clusters. ARI is symmetric and for this reason we also use it for estimating the concordance between any two clustering models.
Model nomenclature
In the Results section, the various models described above are referred to as follows. The model that assumes a uniform (i.e flat) prior over the CCF variables φ jk is the Flat model.
The model that assumes a single-output Gaussian Process prior over the transformed CCF variables ψ jk is the GP0 model. The models assuming a multi-output Gaussian Process prior on ψ jk are labelled GP1 (when Σ K is diagonal), GP2 (when Σ K is full rank) and GP3 (when Λ M K×M K is block-diagonal with cluster-specific h 2 k and τ k parameters), respectively. Each of the models GP0 to GP3 admits exponential (Exp), Mat32, Mat52 or exponentiated quadratic (ExpQ) kernels and are labelled accordingly, e.g. GP0-Exp, GP0-ExpQ, etc.
In total, we examined 17 models. If the number of parameters in the Flat model is n p , the number of parameters in the GP0, GP1, GP2 and GP3 models is n p + 2, n p + K + 1, n p + K + 1 + K(K − 1)/2 and n p + 2K, respectively.
RESULTS
We conducted a series of computational experiments on WES and WGS data from patients with CLL [23, 24] , on TGS data from the liquid biopsy of a patient with melanoma [25] and on simulated data. The aim of these experiments was to demonstrate the application of the above models on longitudinal data and to assess their relative performance.
The case of patient CLL003
First, we demonstrate the application of model GP0-Mat32 on WGS data from patient CLL003 reported in [23] (Fig.1 ; the other models on the same dataset are shown in Fig.2 ).
Details on sequencing and bioinformatics analysis for obtaining this data are given in the original paper. Briefly, peripheral blood was collected at five specific time points during disease progression, treatment and relapse together with a matched buccal swab (for germinal DNA). All samples underwent whole genome sequencing (WGS) followed by bioinformatics analysis, which identified 28 somatic mutations. Fitting the model to this data was performed by maximising the ELBO (see Methods), which can be used for assessing convergence of the estimation algorithm (typically achieved in less than 3K iterations; Fig.1A) .
Following a non-parametric approach for clustering mutations using a Dirichlet Process prior on the cancer cell fractions (see Methods) means that the number of clusters is not selected a priori, but rather estimated along with other model parameters (Fig.1B) . We identified three major mutation clusters: one with median weight ≈35% (i.e. any mutation has approximately 35% probability of belonging to this cluster) and two slightly smaller clusters with median ≈30%. In Fig.1C , Benchmarks on CLL data with 4 or 5 samples
Next, we applied the remaining models on the data from patient CLL003, as well as all models on data from patients CL006 and CLL077 reported in [23] In order to assess the clustering concordance between the two models (i.e. whether they assign the same mutations to the same clusters), we calculated the values of ARI, which were equal to 0.54, 0.79 and 0.58, respectively. This indicates that the two models are not perfectly concordant in any of these three datasets (despite both identifying the same number of clusters) presumably due to the partial overlap between different mutation groups, as illustrated in Fig.2Ai -Ci. One striking difference between the Flat and GP-based models is that while the former estimates the latent state of the tumour only at the timepoints of sample collection (this is indicated by the dashed connecting lines in Fig.2Aiii-Ciii) , the latter provides an estimate of the complete history of this latent state, i.e. both at and between these fixed timepoints. This is a major difference in favour of the use of GP-based models. In the case of Patient 2, the Flat and GP0-Mat32 models identify three and five clusters, respectively (ARI=0.63; Fig.2Di -iii). For comparison, in the original paper, the authors identified seven clusters using PyClone [9] .
In order to further assess the relative performance of different models (and without knowledge of the true clonal state of each tumour), we used the ELBO as performance metric (see Methods). The ELBO provides a lower bound on the marginal likelihood of the data (i.e. the evidence) and, at the same time, it includes an internal mechanism that prevents overfitting. Thus, it is often used in practise for model comparison and selection, with higher ELBO values indicating a better model. As illustrated in Fig.3A , all GP0 models, all but one GP1 models and all but two GP3 models outperform the Flat model on the CLL003
data. The GP2 model, which has by far the largest number of parameters, was the worst performer and it is omitted from the figure. There is a clear trend of decreasing performance with increasing number of parameters among the GP-based models, which is not surprising given that the lower the number of timepoints, the lower the capacity of the data to support overly complex models (as, for example, in the case of GP2 models). In the case of CLL006 ( Fig.3B) , the same trend is observed, although the difference of the GP-based models from the Flat model is less pronounced. In the case of CLL077 (Fig.3C) , models GP0-Mat32
and GP0-ExpQ perform better than the Flat model (although this difference is not partic-ularly pronounced because of the high variance of the ELBO), but the remaining GP-based models perform either clearly worse or comparably to the Flat model. In the case of Patient 2 (Fig.3D) , the GP0 models are again the best performers, unlike GP1 and GP3 models, which are clearly worse than the Flat model. In summary, there is always a member of the relatively parsimonious (in terms of the number of model parameters) GP0 family of models that performs better than the Flat model in the above benchmarks.
Benchmarks on CLL and melanoma data with 10 or 13 samples
Subsequently, we tested our models on longitudinal genomic data involving a higher number of timepoints. The first dataset comes from Patient 1 in [24] . A total of 13 peripheral blood mononuclear cell samples (P1.1 to P1.13) were collected over the course of 6.5 years and underwent targeted sequencing (TGS). Samples were collected before or after treatment commenced. In particular, sample P1.1 was collected before the patient received a stem cell transplant and the same holds for sample P1.8. Germinal DNA was obtained from a buccal mucosa sample and bioinformatics analysis identified 46 somatic mutations over all 13 samples ( Fig.4A ; see original paper for details). Model GP0-Mat32 identified nine mutation clusters (Fig.4B) , while the Flat model identified five (Fig.4C ). In comparison, in the original paper, the authors estimated four clusters using PyClone [9] . Overall, models GP0, GP1
and GP2 perform better than the Flat model, unless an exponentiated quadratic kernel (ExpQ) is used (Fig.4D ). We speculate that this is because ExpQ encodes perfectly smooth dynamics, which presumably cannot model sufficiently well the non-smooth bottleneck points P1.2 and P1.8 which precede stem cell transplantation. Model GP3-Exp is also performing better than the Flat model.
The second multi-sample dataset comes from the liquid biopsy of a patient with metastatic melanoma [25] . Peripheral blood samples were collected at 10 different time points during pre-treatment, post-treatment and relapse over the course of 13 months. Germinal DNA was obtained from normal peripheral blood leucocytes. Targeted sequencing was conducted on extracted cell-free DNA followed by bioinformatics analysis, which revealed 63 somatic mutations. Visual inspection of the data indicates the absence of a definitive cluster structure ( Fig.5A ) and, for this reason, this is an interesting dataset to use for model evaluation. Both the Flat and GP0-Exp models identified five mutation clusters with little concordance between them (ARI=0.27) due to the extended overlap between different mutations bundles (Fig.5B,C) . The median performance of model GP0-Exp is nominally higher than the Flat model, although it is doubtful whether the difference is substantial due to the high variance of the ELBO (Fig.5D ). The remaining GP-based models perform worse than either Flat or GP0-Exp.
Computational experiments on simulated data
Overall, models GP0 (particularly GP0-Exp) perform at least as well as the Flat model in all the above datasets. More complex models (i.e. models with a larger number of parameters), such as GP1, GP2 and GP3, require a higher number of longitudinally collected samples for improved performance (Fig.4) . However, this is not a sufficient condition, since data of low complexity (i.e. with trivial or non-obvious cluster structure and dynamics) can negatively affect the performance of the GP-based models (Fig.5) .
We wanted to test whether these trends (i.e. the reduction in the performance of the GP-based models in relation to the Flat model as data size and complexity decreases) can be replicated using synthetic genomic data. For a given number of samples M , mutations N and mutation clusters K, data were simulated as follows (see source code on github for details): a) for each sample j, we randomly choose a purity value ρ j between 80% and 90% and a random collection time t j (with the first sample collected at time 0 and the last at time 1); b) for each cluster k, we sample a set of values {ψ jk } j,k from a Gaussian process prior with squared amplitude h 2 and inverse squared time scale τ ; we calculate each φ jk as a sigmoid function of ψ jk ; c) for each mutation i, we randomly sample a cluster membership indicator z i between 1 and K; d) finally, for each mutation i in each sample j, we sample the total number of reads R ij from the empirical distribution of total reads in the data and then the number of mutated reads r ij from a Binomial distribution: r ij ∼ Bin(R ij , 1 2 ρ j φ jz i ).
We generated data with M = {3, 6, 12}, N = {25, 50, 100} and K = {2, 4, 8}. For h 2 and τ , we used the values {1, 10, 20} and {1, 10, 100}, respectively, which cover the range of values estimated from the actual data in the previous sections. For each of the 243 combinations of these parameters, we generated 3 replicates, which leads to a total of 729 datasets. Each such dataset was processed using the Flat, GP0-Exp and GP0-Mat32 models (which were top performers on the actual data) and their performance was assessed against the true cluster structure of the dataset.
We In this paper, we proposed a statistical methodology for clonal deconvolution based on longitudinal data, which explicitly takes into account the temporal spacing of sample collection. Our approach combines two Bayesian non-parametric statistical frameworks, namely Dirichlet Process Mixture Models (for clustering in the absence of prior knowledge on the number of clusters supported by the data) and Gaussian Process Latent Variable Models (for modelling the time-dependence of clone prevalence without any explicit assumptions on the form of this dependence). Using a combination of experimental data from patients with CLL or melanoma, as well as synthetic data simulated using experimental data as template, we demonstrate that there are advantages in this approach, as long as data of sufficient volume and complexity are available. When this is not the case, our methodology still manages to reconstruct the time dependence of mutation clusters continuously in time (i.e. at and between sampling timepoints) from a small number of sequentially collected samples.
CLL is an ideal experimental model for the study of cancer evolution, because it develops over many years and because the collection of a long sequence of blood samples from the same patient for genomic analysis is easy, at least when compared to solid tumours. Thus, we expect that our methodology will find applications in the study of CLL and other liquid cancers. It can also be used as a general purpose clustering tool for identifiying populations of mutations based on sequencing of circulating tumour DNA obtained through a liquid biopsy.
As with other approaches for clustering mutations based on bulk sequencing data, a phylogeny is not derived directly, but it can be calculated retrospectively using the output of our method as input to bespoke software [44] [45] [46] . Furthemore, single-cell sequencing promises to alleviate the confounding of clones inherent in methods based on bulk sequencing by permitting direct observation of the genotypes of the cells that compose each clone. However, it is in turn plaqued by its own technical limitations, namely high levels of noise, error rates and missing values [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] .
In conclusion, we propose that taking into account information on the temporal spacing 
